vs
Pacira BioSciences, Inc.（PCRX）与Rocket Lab Corp（RKLB）财务数据对比。点击上方公司名可切换其他公司
Pacira BioSciences, Inc.的季度营收约是Rocket Lab Corp的1.1倍（$196.9M vs $179.7M），Rocket Lab Corp同比增速更快（35.7% vs 5.1%），Pacira BioSciences, Inc.自由现金流更多（$43.5M vs $-114.2M），过去两年Rocket Lab Corp的营收复合增速更高（39.2% vs 8.5%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
Rocket Lab是公开上市的航空航天制造商及发射服务提供商，旗下Electron轨道火箭主打小型卫星发射，截至2026年1月已成功完成超75次任务，是全球现役发射次数最多的小型运载火箭。公司还开发了Electron的亚轨道改型HASTE用作高超音速技术测试平台，下一代可复用中型运载火箭Neutron目前也在研发中。
PCRX vs RKLB — 直观对比
营收规模更大
PCRX
是对方的1.1倍
$179.7M
营收增速更快
RKLB
高出30.6%
5.1%
自由现金流更多
PCRX
多$157.7M
$-114.2M
两年增速更快
RKLB
近两年复合增速
8.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $196.9M | $179.7M |
| 净利润 | — | $-52.9M |
| 毛利率 | 79.5% | 38.0% |
| 营业利润率 | 1.2% | -28.4% |
| 净利率 | — | -29.5% |
| 营收同比 | 5.1% | 35.7% |
| 净利润同比 | — | -1.1% |
| 每股收益（稀释后） | $0.05 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXRKLB
| Q4 25 | $196.9M | $179.7M | ||
| Q3 25 | $179.5M | $155.1M | ||
| Q2 25 | $181.1M | $144.5M | ||
| Q1 25 | $168.9M | $122.6M | ||
| Q4 24 | $187.3M | $132.4M | ||
| Q3 24 | $168.6M | $104.8M | ||
| Q2 24 | $178.0M | $106.3M | ||
| Q1 24 | $167.1M | $92.8M |
净利润PCRXRKLB
| Q4 25 | — | $-52.9M | ||
| Q3 25 | $5.4M | $-18.3M | ||
| Q2 25 | $-4.8M | $-66.4M | ||
| Q1 25 | $4.8M | $-60.6M | ||
| Q4 24 | — | $-52.3M | ||
| Q3 24 | $-143.5M | $-51.9M | ||
| Q2 24 | $18.9M | $-41.6M | ||
| Q1 24 | $9.0M | $-44.3M |
毛利率PCRXRKLB
| Q4 25 | 79.5% | 38.0% | ||
| Q3 25 | 80.9% | 37.0% | ||
| Q2 25 | 77.4% | 32.1% | ||
| Q1 25 | 79.7% | 28.8% | ||
| Q4 24 | 78.7% | 27.8% | ||
| Q3 24 | 76.9% | 26.7% | ||
| Q2 24 | 75.1% | 25.6% | ||
| Q1 24 | 71.6% | 26.1% |
营业利润率PCRXRKLB
| Q4 25 | 1.2% | -28.4% | ||
| Q3 25 | 3.5% | -38.0% | ||
| Q2 25 | 4.7% | -41.3% | ||
| Q1 25 | 1.2% | -48.3% | ||
| Q4 24 | 13.2% | -38.9% | ||
| Q3 24 | -82.8% | -49.5% | ||
| Q2 24 | 15.9% | -40.7% | ||
| Q1 24 | 7.9% | -46.4% |
净利率PCRXRKLB
| Q4 25 | — | -29.5% | ||
| Q3 25 | 3.0% | -11.8% | ||
| Q2 25 | -2.7% | -46.0% | ||
| Q1 25 | 2.8% | -49.5% | ||
| Q4 24 | — | -39.5% | ||
| Q3 24 | -85.1% | -49.6% | ||
| Q2 24 | 10.6% | -39.2% | ||
| Q1 24 | 5.4% | -47.7% |
每股收益（稀释后）PCRXRKLB
| Q4 25 | $0.05 | $-0.09 | ||
| Q3 25 | $0.12 | $-0.03 | ||
| Q2 25 | $-0.11 | $-0.13 | ||
| Q1 25 | $0.10 | $-0.12 | ||
| Q4 24 | $0.38 | $-0.11 | ||
| Q3 24 | $-3.11 | $-0.10 | ||
| Q2 24 | $0.39 | $-0.08 | ||
| Q1 24 | $0.19 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $238.4M | $1.0B |
| 总债务越低越好 | $372.2M | $152.4M |
| 股东权益账面价值 | $693.1M | $1.7B |
| 总资产 | $1.3B | $2.3B |
| 负债/权益比越低杠杆越低 | 0.54× | 0.09× |
8季度趋势，按日历期对齐
现金及短期投资PCRXRKLB
| Q4 25 | $238.4M | $1.0B | ||
| Q3 25 | $246.3M | $976.7M | ||
| Q2 25 | $445.9M | $688.1M | ||
| Q1 25 | $493.6M | $428.4M | ||
| Q4 24 | $484.6M | $419.0M | ||
| Q3 24 | $453.8M | $442.4M | ||
| Q2 24 | $404.2M | $496.8M | ||
| Q1 24 | $325.9M | $492.5M |
总债务PCRXRKLB
| Q4 25 | $372.2M | $152.4M | ||
| Q3 25 | $376.7M | $347.0M | ||
| Q2 25 | $580.5M | $346.5M | ||
| Q1 25 | $583.4M | $345.9M | ||
| Q4 24 | $585.3M | $345.4M | ||
| Q3 24 | — | $61.2M | ||
| Q2 24 | — | $64.2M | ||
| Q1 24 | — | $66.8M |
股东权益PCRXRKLB
| Q4 25 | $693.1M | $1.7B | ||
| Q3 25 | $727.2M | $1.3B | ||
| Q2 25 | $757.8M | $688.5M | ||
| Q1 25 | $798.5M | $431.3M | ||
| Q4 24 | $778.3M | $382.5M | ||
| Q3 24 | $749.6M | $419.8M | ||
| Q2 24 | $879.3M | $455.2M | ||
| Q1 24 | $892.2M | $478.9M |
总资产PCRXRKLB
| Q4 25 | $1.3B | $2.3B | ||
| Q3 25 | $1.3B | $2.2B | ||
| Q2 25 | $1.5B | $1.6B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.5B | $1.2B | ||
| Q2 24 | $1.6B | $1.2B | ||
| Q1 24 | $1.6B | $1.2B |
负债/权益比PCRXRKLB
| Q4 25 | 0.54× | 0.09× | ||
| Q3 25 | 0.52× | 0.27× | ||
| Q2 25 | 0.77× | 0.50× | ||
| Q1 25 | 0.73× | 0.80× | ||
| Q4 24 | 0.75× | 0.90× | ||
| Q3 24 | — | 0.15× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $43.7M | $-64.5M |
| 自由现金流经营现金流 - 资本支出 | $43.5M | $-114.2M |
| 自由现金流率自由现金流/营收 | 22.1% | -63.6% |
| 资本支出强度资本支出/营收 | 0.1% | 27.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $136.7M | $-321.8M |
8季度趋势，按日历期对齐
经营现金流PCRXRKLB
| Q4 25 | $43.7M | $-64.5M | ||
| Q3 25 | $60.8M | $-23.5M | ||
| Q2 25 | $12.0M | $-23.2M | ||
| Q1 25 | $35.5M | $-54.2M | ||
| Q4 24 | $33.1M | $-2.4M | ||
| Q3 24 | $53.9M | $-30.9M | ||
| Q2 24 | $53.2M | $-13.0M | ||
| Q1 24 | $49.1M | $-2.6M |
自由现金流PCRXRKLB
| Q4 25 | $43.5M | $-114.2M | ||
| Q3 25 | $57.0M | $-69.4M | ||
| Q2 25 | $9.3M | $-55.3M | ||
| Q1 25 | $26.9M | $-82.9M | ||
| Q4 24 | $31.0M | $-23.9M | ||
| Q3 24 | $49.8M | $-41.9M | ||
| Q2 24 | $51.6M | $-28.3M | ||
| Q1 24 | $46.3M | $-21.8M |
自由现金流率PCRXRKLB
| Q4 25 | 22.1% | -63.6% | ||
| Q3 25 | 31.7% | -44.8% | ||
| Q2 25 | 5.1% | -38.3% | ||
| Q1 25 | 15.9% | -67.6% | ||
| Q4 24 | 16.6% | -18.1% | ||
| Q3 24 | 29.6% | -40.0% | ||
| Q2 24 | 29.0% | -26.7% | ||
| Q1 24 | 27.7% | -23.5% |
资本支出强度PCRXRKLB
| Q4 25 | 0.1% | 27.6% | ||
| Q3 25 | 2.2% | 29.6% | ||
| Q2 25 | 1.5% | 22.2% | ||
| Q1 25 | 5.1% | 23.4% | ||
| Q4 24 | 1.1% | 16.3% | ||
| Q3 24 | 2.4% | 10.5% | ||
| Q2 24 | 0.9% | 14.4% | ||
| Q1 24 | 1.7% | 20.7% |
现金转化率PCRXRKLB
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | — | ||
| Q1 24 | 5.47× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
RKLB
| Products | $94.0M | 52% |
| Transferred Over Time | $87.3M | 49% |
